Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "continuous renal replacement therapy"

Biomarkers of Inflammation during Continuous Renal Replacement Therapy: Sensors, Players, or Targets A Reply to the Letter by Villa et al.
Sexual Development

Biomarkers of Inflammation during Continuous Renal Replacement...

General Please address all your queries or problem reports to the Pay-per-View Customer Service at info@karger.com referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ... Sexual Development, 1 month ago

14 images for continuous renal replacement therapy

Sexual Development, 1 month ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
MDLinx, 1 day ago
Securities Technology Monitor

Rockwell Medical Closes $58.5 Million Public Offering of Common Stock

Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary ...
 Individual.com7 hours ago Rockwell Medical Prices $58.5 Million Public Offering of Common Stock  Individual.com5 days ago Rockwell Medical Announces $55 Million Proposed Public Offering of Common Stock  Individual.com1 week ago Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at the American Society of Nephrology (ASN) Meeting November 2014  BizWire Express2 weeks ago
[x]  

AMICUS THERAPEUTICS : Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology

CRANBURY, N.J. and PHILADELPHIA , Nov. 15, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important ...
 4 Traders1 week ago Amicus Therapeutics, Inc. Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology  BioSpace1 week ago Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology  PipelineReview1 week ago
[x]  

Re: Concerns over use of hydroxyethyl starch solutions

Hartog and colleagues argue (1) against the decision of the European Medicines Agency (EMA) (2) to allow the continued use of hydroxyethyl starch (HES), and advise physicians to avoid HES solutions altogether. They base their advice primarily on ...
 British Medical Journal1 week ago Acrux : European Medicines Agency Testosterone update  4 Traders1 day ago

Ears and Hearing Effects Continue to Reverberate after Boston Marathon Bombing

Acute kidney injury occurs frequently in Ebola virus disease; however, providing hemodialysis to these patients was previously thought to be too risky. Clinicians recently accomplished the first known successful delivery of renal replacement therapy ...
 Infrosoft1 week ago

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript

Operator Good day, ladies and gentlemen. Welcome to the Amicus 3Q Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at ...
 Seeking Alpha2 weeks ago

ARGOS THERAPEUTICS INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing in "Item 1. Financial Statements" in this ...
 Pharmacy Choice1 week ago Corporate Information, Status of Operations and Management Plans  TMC Net2 weeks ago NEWLINK GENETICS CORP - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  TMC Net2 weeks ago INSPIREMD : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)  4 Traders2 weeks ago

New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--November 06, 2014-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and ...
 Scottrade2 weeks ago Merck : New Studies Investigating the Use of KEYTRUDA┬« (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time  4 Traders2 weeks ago Merck & Co. (MRK) Scores Another Breakthrough For KEYTRUDA┬« 10/27/2014  ClinicSpace3 weeks ago Merck & Co. Scores Another Breakthrough For KEYTRUDA┬«  BioSpace4 weeks ago
[x]  

St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B

MEMPHIS, Tenn. , Nov. 19, 2014 /PRNewswire-USNewswire/ -- Gene therapy developed at St. Jude Children's Research Hospital, University College London (UCL) and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by ...
 BioSpace5 days ago Gene therapy provides safe, long-term relief for patients with severe hemophilia B  MoneyShow.com6 days ago
[x]  

Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates

Important New Migalastat Data on Cardiac and Other Key Secondary Endpoints for Study 012 to be Presented At American Society of Nephrology Meeting on November 15 Migalastat Pre-Submission Meeting with European Regulators On Track for 4Q14 ...
 Tamar Securities2 weeks ago Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program  Industrial Info Financials1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less